Media stories about Presbia PLC (NASDAQ:LENS) have been trending positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Presbia PLC earned a news sentiment score of 0.28 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 45.6668944326893 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of analysts recently commented on LENS shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Presbia PLC in a report on Tuesday, May 23rd. Rodman & Renshaw dropped their price target on Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, May 22nd. Finally, Zacks Investment Research upgraded Presbia PLC from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $12.00.
Presbia PLC (LENS) traded up 5.6827% during mid-day trading on Monday, reaching $2.5999. The company’s stock had a trading volume of 3,234 shares. Presbia PLC has a 12-month low of $1.86 and a 12-month high of $5.15. The company has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.84. The firm’s market cap is $44.08 million.
COPYRIGHT VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Presbia PLC (LENS) Stock Price” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/08/14/favorable-news-coverage-somewhat-unlikely-to-impact-presbia-plc-lens-stock-price.html.
Presbia PLC Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.